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Highlights	
•	17	New	chloropyramine	analogues	were	designed	and	synthesised.	
•	All	new	compounds	were	evaluated	for	their	activity	in	three	different	breast	cancer	cell	lines.	
•	For	the	most	active	compound	5c,	in	vitro	pharmacokinetic	studies	were	performed.	
ABSTRACT	
Breast	cancer	(BC)	is	the	second	most	common	cancer	worldwide,	accounting	for	25%	of	all	female	
cancers.	Although	the	survival	rate	has	increased	significantly	in	the	past	few	decades,	patients	who	
develop	 secondary	 site	 metastasis	 as	 well	 as	 those	 diagnosed	 with	 triple	 negative	 breast	 cancer	
(TNBC)	 still	 represent	 a	 real	 unmet	 medical	 challenge.	 Previous	 studies	 have	 shown	 that	
chloropyramine	 (C4)	 inhibits	 FAK-VEGFR3	 signaling.	More	 recently,	 C4	 is	 reported	 to	 have	 SASH1	
inducing	 properties.	 However,	 C4	 exerts	 its	 antitumour	 and	 antiangiogenic	 effects	 at	 high	
micromolar	concentrations	(>100	µM)	that	would	not	be	compatible	with	further	drug	development	
against	 invasive	 breast	 cancer	 driven	 by	 FAK	 signaling.	 In	 this	 study,	 molecular	 modeling	 guided	
structural	 modifications	 have	 been	 introduced	 to	 the	 chloropyramine	 C4	 scaffold	 to	 improve	 its	
activity	 in	breast	cancer	cell	 lines.	Seventeen	compounds	were	designed	and	synthesised	and	their	
anti-proliferative	 activity	 was	 evaluated	 against	 three	 human	 breast	 cancer	 lines	 (MDA-MB-231,	
BT474	and	T47D).	Compound	5c	was	identified	to	display	an	average	activity	of	IC50	=	23.5-	31.3	µM,	
which	 represents	 a	 significant	 improvement	 of	 C4	 activity	 in	 the	 same	 assay	 model. Molecular	
modelling	 and	 pharmacokinetic	 studies	 provided	 more	 promising	 insights	 into	 the	 mechanistic	
features	of	this	new	series.	
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1. INTRODUCTION	
Current	 therapeutic	 strategies	 for	breast	 cancer	 (BC)	 are	mainly	directed	 towards	primary	 tumour	
site	histopathology	i.e.	expression	of	estrogen	(ER),	progesterone	(PR)	and	human	epidermal	growth	
factor	2	(HER2)	receptors.	Due	to	 improved	therapeutic	strategies,	the	survival	rate	for	ER-positive	
breast	 cancer	 in	 particular	 has	 increased	 significantly	 in	 the	 past	 few	decades.	However,	 the	 sub-
group	 of	 aggressive	 and	 invasive	 breast	 cancers,	 including	 triple-negative	 disease	 (around	 15%	 of	
cases),	 is	 characterised	 by	 rapid	 relapse	 following	 chemotherapy	 and	 progression	 to	 metastatic	
disease,	with	a	poor	overall	prognosis.1		
Focal	adhesion	kinase	(FAK)	is	a	cytoplasmic	tyrosine	kinase	and	scaffold	protein,	which	is	localised	
to	 focal	adhesions,	and	forms	points	of	contacts	between	cells	and	the	extracellular	matrix.	FAK	 is	
highly	expressed	in	cancer,	acts	as	a	multifunctional	mediator	of	cell	signaling,	and	its	involvement	in	
cancer	cell	proliferation,	invasion	and	metastasis	is	well	documented.2-7	It	is	overexpressed	in	many	
types	of	cancer	such	as	thyroid,	brain,	 liver,	prostate,	breast,	colon,	head	and	neck.	Moreover,	this	
overexpression	 is	 associated	with	 an	 invasive	phenotype	 in	 such	 tumours.7	Numerous	 approaches	
are	 being	 developed	 to	 inhibit	 FAK	 catalytic	 function	 (mainly	 targeting	 the	 Y397	 tyrosine	
phosphorylation	 site),	which	have	 successfully	 led	 to	 the	development	of	 clinical	 stage	FAK	kinase	
inhibitors	 such	 as	 defactinib,	 currently	 in	 Phase	 I/II	 trials	 in	 ovarian,	 non-small	 cell	 lung,	
mesothelioma	 and	 pancreatic	 cancer	 (Verastem,	 Inc.)8	 Alternatively,	 destabilisation	 of	 the	 FAK	
scaffolding	 function	 is	 believed	 to	 be	 an	 advantageous	 and	 potentially	 more	 specific	 strategy	 to	
develop	 FAK	 targeting	 therapeutics	 rather	 than	 focusing	 on	 the	 kinase	 function	 only.7-11	 In	 silico	
screening	of	the	National	Cancer	Institute’s	small	molecule	library	for	compounds	targeting	the	FAK–
VEGFR3	 interactions	 led	 to	 the	 identification	 of	 the	 clinically	 approved	 antihistamine	 drug	
chloropyramine	(C4)	which	belongs	to	the	first	generation	of	H1-antihistamines.12,13	Further	in	vitro	
and	 in	 vivo	 studies	 have	 shown	 that	 treatment	with	C4	 showed	 reduction	 in	 tumour	 burden	 and	
neovascularization	 in	mouse	models	of	breast	 cancer.12	This	activity	has	been	demonstrated,	both	
alone	 and	 synergistically	with	 other	 chemotherapeutic	 agents	 (e.g.	 doxorubicin	 and	 gemcitabine),	
sensitising	 breast	 cancer	 cells	 to	 chemotherapy.12,13	 Moreover,	 C4	 is	 under	 development	 by	
CureFAKtor	 Pharmaceuticals	 LLC,	 and	 received	 orphan	 drug	 designation	 from	 the	 FDA	 in	
combination	with	gemcitabine	for	the	treatment	of	pancreatic	cancer.	14	More	recently,	Burgess	et	al	
have	independently	used	 in	silico	connectivity	mapping	and	 in	vitro	modelling	to	demonstrate	that	
chloropyramine	C4,	increased	SASH1	protein	levels	in	breast	cancer	cells.15	Expression	of	the	SASH1	
protein	 is	 reduced	 in	 a	 range	 of	 human	 cancers	 and	 has	 been	 implicated	 in	 apoptotic	 cancer	 cell	
death.	Although	C4	 is	an	attractive	candidate,	it	exerts	its	antitumour	and	antiangiogenic	effects	at	
high	micromolar	concentrations	(>100	µM).13	In	order	to	get	more	insights	into	the	structure	activity	
relationships	(SAR)	and	improve	the	antitumour	potency	of	C4,	we	introduced	new	chemical	motifs	
into	 the	 scaffold	 of	 C4.	 These	 modifications	 were	 tested	 in	 a	 preliminary	 in	 silico	 study	 that	
suggested	an	improved	interaction	with	the	FAK-FAT	domain.	The	newly	designed	compounds	were	
synthesised	and	screened	in	vitro	against	three	human	breast	cancer	cell	lines	(MDA-MB-231,	BT474	
and	T47D).	Our	findings	show	that	compound	5c,	which	displayed	the	best	anti-proliferative	potency	
amongst	 all	 tested	 analogues,	 is	 a	 novel	 compound	 that	 warrants	 further	 investigation	 as	 a	
candidate	for	breast	cancer	therapy.	
2. METHODS	AND	MATERIALS		
2.1	Lead	optimisation	and	design	of	novel	chloropyramine	(C4)	analogues	
Based	on	the	previous	promising	findings	with	chloropyramine	(C4),12,13	we	sought	to	improve	upon	
the	 chemical	 structure	 of	 C4	 to	 understand	 better	 its	 structure	 activity	 relationship	 (SAR)	 and	 to	
improve	 its	 anti-proliferative	 potency	 (C4	 IC50	 >100	 µM).	 To	 investigate	 the	 impact	 of	 various	
substituents	 of	 C4	 on	 the	 antitumour	 efficacy,	 a	 series	 of	 novel	 derivatives	 were	 designed	 and	
prepared,	as	detailed	in	Figure	1,	and	Schemes	1	and	2.	Structural	modifications	involved	replacing	
the	pyridine	moiety	with	 other	 aromatic	 systems	 containing	 a	 carboxylate	moiety	 to	 enhance	 the	
interaction	with	Lys	1032	within	the	FAK-FAT	domain,	introducing	an	extended	carbon	atom	moiety	
(region	A,	Figure	1)	or	introducing	a	carbonyl	group	into	N,N-dimethylamino	ethyl	side	chain	(region	
C,	 Figure	 1).	 The	 p-chlorobenzyl	 group	 (region	 B,	 Figure	 1)	 was	 retained	 unmodified	 in	 most	
compounds	since	it	is	involved	in	key	interactions	via	a	π-π	stacking	with	the	aromatic	side	chain	of	
Tyr	 925.	 The	 salicylate	 aromatic	 moiety	 replacing	 the	 pyridine	 ring	 was	 reported	 to	 mimic	 the	
phosphorylated	 tyrosine	 (pTyr).16,17	Molecular	modeling	 studies	of	 the	newly	designed	compounds	
showed	improved	binding	interaction	modes	within	the	FAK-FAT	pocket	compared	to	the	parent	C4	
compound	due	to	a	better	orientation	effect	on	the	side	chain	(region	C,	Figure	1).	All	the	prepared	
compounds	were	evaluated	against	three	breast	cancer	lines	 i.e.	MDA-MB-231	(TNBC),	BT474	(ER+,	
HER+)	and	T47D	(ER+,	HER-).	
	
	
	
	
	
	
	
	
	
	
Figure	1.	Chemical	structure	of	chloropyramine	and	regions	of	proposed	structural	modification.	
	
	
2.2	Chemical	synthesis	
The	 first	 series	of	compounds	containing	an	extended	carbon	unit	 in	 the	C4	 skeleton	 (5a-d,	region	A	
modification)	were	synthesised	as	shown	in	Scheme	1.	The	first	step	 involved	reductive	amination	of	
various	 substituted	aromatic	aldehydes	 (1a-d)	with	N,	N-dimethyl-ethylenediamine	2	which	provided	
intermediates	 (3a-d)	 in	good	yields.18	 It	 is	worth	mentioning	that	 the	reaction	conditions	of	 this	step	
were	 optimized	 in	 terms	 of	 solvent	 and	 temperature	 choice	 for	 the	 different	 aldehydes	 used	 (see	
experimental	 section).	These	 intermediates	were	alkylated	with	p-chlorobenzyl	chloride	4	 to	give	 the	
target	 analogues	 (5a-d)	 in	 good	 to	 moderate	 yield	 (57-69	 %).	 Interestingly,	 in	 the	 case	 of	 4-((2-
(dimethylamino)ethylamino)methyl)	 benzonitrile	 3a,	 a	 quaternary	 ammonium	 side	 product	 6	 was	
obtained	alongside	the	expected	product	5a	(in	1:3	ratio,	respectively).	Unexpectedly,	in	the	case	of	2-
cyanobenzaldehyde	 7,	 the	 cyclised	 isoindolenone	 derivative	 8	 was	 isolated	 instead	 of	 the	 desired	
Schiff’s	 base,	 Scheme	 2	 (A).	 A	 plausible	 mechanism	 is	 suggested	 where	 the	 initial	 step	 is	 the	
nucleophilic	 addition	 of	 the	 amine	 2	 to	 the	 formyl	 group	 of	 7	 affording	 the	 adduct	 7a,	 which	
subsequently	cyclises	to	7b	by	intramolecular	nucleophilic	addition	of	the	hydroxyl	group	to	the	cyano	
group	of	7a,	followed	by	conversion	to	the	isoindolenone	derivative	8,	Scheme	2	(B).19	
		
	
	
Scheme	1.	Synthesis	of	compounds	(5a-d).	Reagents	and	conditions:	a)	i.	3a	and	3d,	(MeOH,	rt,	4h),	3b	(DCE,	
reflux,	4h),	3c	(AcOH,	6h),	ii.	NaBH(OAc)3,	rt,	24h,	b)	THF,	rt.	24h.	
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Scheme	2;	A)	Synthesis	of	isoindolene	derivative	8.	Reagents	and	conditions;	a)	MeOH,	rt,	4h,	NaBH(OAc)3,	rt,	
24h.	B)	proposed	mechanism	for	the	formation	of	the	isoindolenone	derivative	8. 
	
The	 second	 series	 of	 compounds	 (13a-m),	 featuring	 an	 additional	 carbonyl	 group	 in	 the	 N,N-
dimethylamino	ethyl	 side	 chain	moiety	of	 C4,	were	prepared	according	 to	Scheme	3	 (A).	 The	 first	
step	 involved	a	 reductive	amination	 reaction20	between	 the	corresponding	aniline	derivative	 (9a-l)	
and	p-halobenzaldehyde	 (10a	 or	10b)	 to	 give	 the	 key	 intermediates	 (11a-l).	 The	 final	 compounds	
were	obtained	by	 reacting	N,N-dimethylaminoacetyl	 chloride	hydrochloride	12	with	 intermediates	
(11a-l)	 in	 tetrahydrofuran	 at	 room	 temperature.	 The	 reductive	 amination	 of	 5-amino-2-
hydroxybenzoic	acid	with	p-chlorobenzaldehyde	(10a)	was	not	feasible	due	to	the	instability	of	the	
intermediate	product	(11m).	For	this	reason,	we	managed	to	get	the	corresponding	target	product	
13m	 via	 the	 hydrolysis	 of	 13c	 using	 NaOH	 solution	 in	 a	 very	 good	 yield	 (92	 %),	 Scheme	 3	 (A).	
Interestingly,	 double	 reductive	 amination	occurred	 in	 the	 case	of	 compound	9m	 to	 give	14	which	
was	hydrolysed	to	15	using	NaOH.	The	structures	of	all	the	synthesised	compounds	were	confirmed	
using	 analytical	 and	 spectroscopic	 data	 (NMR,	mass	 spectrometry),	which	were	 in	 full	 accordance	
with	their	depicted	structure.	All	final	compounds	were	purified	and	tested	as	free	bases.		
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Scheme	3.	A)	Synthesis	of	compounds	(13a-m).	Reagents	and	conditions:	a)	MeOH,	rt,	4h,	NaBH(OAc)3,	24h,	b)	
THF,	rt.	24h.	B)	Synthesis	of	compounds	14	and	15.	Reagents	and	conditions:	a)	DCE,	reflux,	4h,	NaBH(OAc)3,	
r.t.	24h,	b)	NaOH,	MeOH,	reflux,	4hr.	
	
3. RESULTS	AND	DISCUSSION	
3.1	Cell	Viability	Assay	
The	 anti-proliferative	 activity	 of	 all	 the	 synthesised	 compounds	 5a-d,	 6,	 8,	 13a-m,	 14	 and	 15	 was	
evaluated	 as	 free	bases	 against	 three	human	breast	 cancer	 cell	 lines;	MDA-MB-231	 (TNBC),	 BT474	
(ER+,	HER+)	and	T47D	(ER+,	HER-).	Chloropyramine	C4	was	used	as	a	control	drug.	The	corresponding	
cell	 lines	 were	 seeded	 the	 day	 before	 incubation,	 then	 incubated	 for	 72	 h	 with	 the	 different	
concentrations	of	 compound	 tested.	CellTiter	Glo	 reagent	 (25	μL)	was	added	 to	 the	 cell	plate.	 The	
luminescence	was	recorded	after	10	mins	on	a	PerkinElmer	Envision	instrument.	All	the	twenty-one	
compounds	were	tested	at	10	concentrations	in	half	 log	increments	up	to	100	μM	in	triplicate.	The	
results	 indicated	 that	 three	 compounds	 (5c,	 6	 and	 15)	 have	 better	 anti-proliferative	 activity	 than	
chloropyramine	C4,	which	did	not	 show	any	anti-proliferative	 activity	 up	 to	100	μM	concentration	
across	the	three	BC	cell	 lines.	The	most	active	compound	5c	showed	micromolar	activity	across	the	
three	BC	 cell	 lines;	 (MDA-MB-231,	 IC50	 =	 23.5	μM),	 (BT474,	 IC50	 =	 73.2	μM)	 and	 (T47D,	 IC50	 =	 31.3	
μM),	 Figure	 2A.	 Interestingly,	 the	 quaternary	 ammonium	 compound	 6	 and	 the	 double	 reductive	
amination	 product	 15,	 displayed	 better	 anti-proliferative	 activity	 than	 C4,	 Figure	 2B	 and	 C,	
respectively.	 All	 the	 other	 tested	 analogues	 showed	 no	 observed	 improvement	 in	 the	
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antiproliferative	 activity	 over	 the	 parent	 compound	 C4	 (all	 compounds	 were	 tested	 at	 maximum	
concentration	of	100	µM).	
	
Figure	2.	Anti-proliferative	activity	of	compounds	5c	(A),	6	(B)	and	15	(C)	against	three	human	breast	cancer	
cell	lines;	MDA-MB-231,	BT474	and	T47D.	
3.2	Molecular	modelling	
In	 silico	 docking	 was	 performed	 on	 all	 the	 designed	 analogues	 using	 the	 downloaded	 crystal	
structure	 of	 FAK	 (PDB	 ID:	 1K05).21	 The	 chemical	 structures	 of	 the	 compounds	 were	 constructed,	
rendered	and	minimised	with	the	MMFF94x	force	field	in	MOE.	Docking	simulations	were	performed	
using	 Glide	 SP	 in	 Maestro	 (Glide,	 version	 9.5,	 Schrödinger,	 LLC,	 New	 York,	 NY.	 http://www.	
schrodinger.com).	Based	on	the	surface	representation	of	the	FAK-FAT	domain,	there	appears	to	be	
an	 improved	 interaction	 over	 the	 parent	C4	upon	 the	 introduction	 of	 an	 extended	 carbon	 linker,	
compounds	 (5a-d),	 or	 introduction	of	 a	 carbonyl	 group	as	 in	 compounds	 (13a-m)	 into	 the	general	
chloropyramine	scaffold.	Figure	3A	shows	the	predicted	docking	mode	of	the	most	active	compound	
5c	 compared	 to	 that	 of	 the	 parent	 compound	C4.	 The	 computational	 study	 showed	 an	 improved	
interaction	between	the	N,N-dimethylamino	ethyl	side	chain	and	Asp	1036	of	5c.	Compound	5c	sits	
in	 a	 relatively	 polar	 cavity	 surrounded	by	 residues	 Ser	 910,	 Thr	 929,	 Lys	 1032,	 and	Asp	1036.	 Key	
interactions	of	5c	 include	 two	H-bonds	between	 the	N,N-dimethylamino	ethyl	group	and	both	 the	
side	chain	carboxylate	group	of	 residue	Asp	1036	and	the	backbone	carbonyl	group	of	Pro	911.	 In	
addition,	 hydrophobic	 interactions	 were	 observed	 between	 the	 p-chlorobenzyl	 group	moiety	 and	
the	 surrounding	 hydrophobic	 pocket	 formed	 of	 residues	 Tyr	 925,	 Val	 928,	 Val	 932,	 and	 Leu	 1035	
(Figure	 3A).	 The	 relatively	 higher	 activity	 of	 compound	 5c	 appears	 to	 be	 a	 result	 of	 the	 better	
directing	effect	of	the	N,N-dimethylamino	side	chain	conferred	by	the	extra	carbon	moiety.	On	the	
other	 hand,	 according	 to	 our	 model,	 the	 introduction	 of	 the	 carbonyl	 group	 into	 the	 N,N-
dimethylamino	 ethyl	 moiety	 of	 C4	 (e.g.	 13a)	 showed	 an	 improved	 effect	 on	 orienting	 the	 N,N-
dimethylamino	 ethyl	 group	 into	 the	 polar	 pocket	 around	 Asp	 1036	 as	well	 as	 directing	 the	 other	
aromatic	 group	 to	 the	 hydrophobic	 pocket,	 Figure	 3B. However,	 none	 of	 the	 carbonyl	 containing	
compounds	 (13a-m)	 were	 able	 to	 demonstrate	 any	 better	 anti-proliferative	 activity	 than	 C4,	
probably	because	of	the	reduced	basicity	of	the	N,N-dimethylamino	moiety	upon	the	introduction	of	
the	 carbonyl	 group.	 Generally,	 our	 study	 of	 the	 two	modified	 series	 of	 compounds	 suggests	 that	
more	 substantial	 structural	 modifications	 of	 C4	 are	 needed	 to	 significantly	 improve	 the	 anti-
proliferative	activity	in	BC	cell	lines.	
	
Figure	3.	A)	Superposition	of	the	predicted	binding	mode	of	compound	5c	(grey)	versus	C4	(green)	showing	
hydrogen	bond	interactions	(blue	dashed	line)	with	key	amino	acids;	Pro	911	and	Asp	1036.		B)	compound	13a	
(grey)	versus	C4	(green);	both	are	inside	the	pocket	of	FAK-FAT	domain	(golden	yellow	ribbon	representation).	
	
3.3	In	vitro	aqueous	solubility	and	microsomal	metabolic	stability	
Subsequently,	 in	 vitro	pharmacokinetic	 studies	 of	 the	most	 active	 compound	5c	were	 performed.	
The	 in	vitro	aqueous	solubility	was	investigated	using	five	concentrations	of	5c	 i.e	 (1,	3,	10,	30	and	
100	 μM),	 which	 were	 incubated	 at	 37	 °C	 for	 2	 hr.	 The	 estimated	 precipitation	 range	 (lower	 and	
upper	bound)	and	a	mid-range	value	were	calculated	for	5c.	Nicardipine	and	pyrene	are	included	as	
control	 compounds.	 The	 results	 show	 that	 compound	5c	 has	 a	 very	 good	 aqueous	 solubility	with	
estimated	 precipitation	 range	 100	 µM	 (lower	 bound)	 and	 >100	 µM	 (upper	 bound),	 Table	 1.	 This	
relatively	high	aqueous	solubility	could	prove	to	be	a	possible	solution	to	the	sedation	side	effect	of	
chloropyramine	because	of	 its	 ability	 to	 cross	 the	 blood	brain	 barrier	 (BBB).15	 The	 calculated	 logP	
values	(C4	=	3.99,	5c=	4.42)	are	similar	but	tPSA	values	(C4	=	18.84,	5c=	32.78)	suggest	that	5c	is	less	
likely	to	cross	the	BBB.	
Furthermore,	the	metabolic	stability	of	5c	was	tested	in	human	liver	microsomes.	Compound	5c	was	
incubated	 for	45	min	with	pooled	 liver	microsomes	and	 the	 intrinsic	clearance	 (CLint)	and	half-life	
(t1/2)	values	were	calculated	based	on	5	time	points.	The	values	of	intrinsic	clearance	(CLint)	as	well	as	
half-life	values	of	5c	compared	to	control	compounds,	dextromethorphan	and	verapamil,	are	shown	
in	Table	2.	 	Compound	5c	has	microsomal	half-life	(t1/2)	of	59.4	minutes,	which	exceeds	that	of	the	
registered	 drug	 controls	dextromethorphan	 (t1/2	 =	 48.2	mins)	 and	 verapamil	 (t1/2	 =	 8.0	mins),	 and	
represents	a	good	starting	point	for	optimisation	towards	a	daily	administrable	product.	
compound	
Estimated	Precipitation	Range	(µM)	
Lower	bound	 Upper	bound	 Calculated	Mid-range	
5c	 100	 >100	 >100	
nicardipine	 10	 30	 20	
pyrene	 3	 10	 6.5	
	
Table	1.	In	vitro	aqueous	solubility	of	5c	versus	control	compounds	(nicardipine	and	pyrene)	in	buffered	
aqueous	solution	
	
	 CLint	(uL/min/mg	protein)	 t1/2	(min)	
5c	 23.3	 59.4	
dextromethorphan	 28.8	 48.2	
verapamil	 173.0	 8.0	
 
Table	2.	In	vitro	metabolic	stability	of	5c	versus	control	compounds	(dextromethorphan	and	verapamil)	in	
human	liver	microsomes;	CLint:	theoretical	unrestricted	maximum	clearance	of	unbound	drug	by	an	eliminating	
organ,	in	absence	of	blood	or	plasma	protein	binding	limitations,	t1/2	is	the	half-life.	
	
4. Conclusion	
In	this	study,	two	series	of	novel	chloropyramine	C4	analogues	were	designed	and	synthesised.	The	
anti-proliferative	 activity	 of	 compounds	 (5a-d)	 and	 (13a-m)	 was	 evaluated	 as	 free	 bases	 in	 vitro	
across	three	human	breast	cancer	cell	lines;	MDA-MB-231	(TNBC),	BT474	(ER+,	HER+)	and	T47D	(ER+,	
HER-).	 The	 results	 identified	compound	5c	as	having	 the	most	 significant	anti-proliferative	activity,	
displaying	micromolar	 activity	 across	 the	 three	breast	 cancer	 cell	 lines;	 (MDA-MB-231,	 IC50	 =	 23.5	
μM),	 (BT474,	 IC50	 =	 73.2	 μM)	 and	 (T47D,	 IC50	 =	 31.3	 μM).	 This	 activity	 represents	 a	 significant	
improvement	 to	 the	 chloropyramine	C4,	which	did	not	display	any	anti-proliferative	activity	up	 to	
100	 μM.	 Further	 pharmacokinetic	 study	 showed	 that	 5c	 performed	 well	 in	 both	 the	 aqueous	
solubility	 and	microsomal	metabolic	 stability	 analysis.	 Considering	 the	 above	 findings,	 it	 could	 be	
concluded	 that	 5c	 represents	 a	 promising	 basis	 for	 further	 development	 of	 breast	 cancer	
therapeutics	targeting	the	FAK	scaffolding	domain.		
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All	 chemicals	 were	 purchased	 from	 Sigma-Aldrich	 or	 Alfa	 Aesar	 and	 were	 used	 without	 further	
purification.	Thin	Layer	Chromatography	(TLC):	pre-coated	aluminium	backed	plates	(60	F254,	0.2	mm	
thickness,	Merck)	were	visualized	under	both	short	and	long	wave	UV	light	(254	and	366	nm).	Flash	
column	chromatography	was	carried	out	using	silica	gel	supplied	by	Fisher	(60A,	35-70	µm).	1H	NMR	
(500	MHz),	13C	NMR	(125	MHz)	and	19F	NMR	(470	MHz)	spectra	were	recorded	on	a	Bruker	Avance	
500	MHz	 spectrometer	 at	 25°	 C.	 Chemical	 shifts	 (δ)	 are	 expressed	 in	 parts	 per	million	 (ppm)	 and	
coupling	constants	(J)	are	given	in	hertz	(Hz).	The	following	abbreviations	are	used	in	the	assignment	
of	 NMR	 signals:	 s	 (singlet),	 bs	 (broad	 singlet);	 d	 (doublet),	 t	 (triplet),	 q	 (quartet),	 qn	 (quintet),	m	
(multiplet),	dd	(doublet	of	doublet),	dt	(doublet	of	triplet),	td	(triple	doublet);	dq	(double	quartet),	m	
(multiplet),	 dm	 (double	 multiplet).	 Mass	 spectrometry	 was	 performed	 on	 a	 Bruker	 Daltonics	
microTof-LC	system	or	as	a	service	through	the	EPSRC	National	Mass	Spectrometry	centre	(Swansea,	
UK).	
	
4-((2-(Dimethylamino)ethylamino)methyl)benzonitrile	 (3a)	 yield	 	 94	 %.	 To	 a	 solution	 of	 4-
cyanobenzaldehyde	 (1a;	 1.5	 mmol)	 in	MeOH	 (25	mL)	 was	 added	 dropwise	 2-dimethylaminoethyl	
amine	 (2;	 1.8	 mmol).	 The	 solution	 was	 stirred	 at	 room	 temperature	 for	 4h,	 sodium	 borohydride	
(0.75	mmol)	was	added,	and	the	mixture	was	stirred	at	room	temperature	for	24h.	The	progress	of	
the	reaction	was	monitored	by	TLC.	The	solution	was	then	dried	in	vacuo,	and	the	crude	residue	was	
purified	by	column	chromatography	eluting	with	CH2Cl2.	1H	NMR	(MeOD)	δ	7.69	(d,	J=8	Hz,	2H,	ArH),	
7.55	(d,	J=7.5	Hz,	2H,	ArH),	4.84	(bs,	1H,	NH),	3.86	(s,	2H,	CH2),	2.71	(t,	J=5.5	Hz,	2H,	CH2),	2.50	(t,	J=6	
Hz,	 2H,	 CH2),	 2.25	 (s,	 6H,	 2xCH3),	 13C	NMR	 (MeOD)	δ	 145.60	 (ArC),	 131.99	 (ArCH),	 128.95	 (ArCH),	
118.50	(ArCN),	110.49	(ArC),	58.26	(CH2),	52.65	(CH2),	45.89	(CH2),	44.40	(2CH3).	MS	[ESI,	m/z]:	204.1	
[M+H].	
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Methyl	 4-(((2-(dimethylamino)ethyl)amino)methyl)benzoate	 (3b)	 yield	 92	 %.	 To	 a	 solution	 of	
methyl	 4-formylbenzoate	 (1b;	 1.5	 mmol)	 in	 DCE	 (25	 mL)	 was	 added	 dropwise	 2-
dimethylaminoethylamine	 (2;	 1.8	 mmol).	 The	 solution	 was	 heated	 at	 reflux	 for	 4h,	 sodium	
triacetoxyborohydride	 (2.4	 mmol)	 was	 then	 added	 to	 the	 mixture	 which	 was	 stirred	 at	 room	
temperature	 for	 24h.	 The	 progress	 of	 the	 reaction	was	monitored	 by	 TLC.	 The	 solution	was	 then	
dried	 in	 vacuo,	 and	 the	 crude	 residue	 was	 purified	 by	 column	 chromatography	 eluting	 with	
CH2Cl2/CH3OH;	90:10.	1H	NMR	(MeOD)	7.99	(d,	J=8.5	Hz,	2H,	ArH),	7.48	(d,	J=8	Hz,	2H,	ArH),	3.91	(s,	
3H,	CH3),	3.85	(s,	2H,	CH2),	2.72	(t,	J=7	Hz,	2H,	CH2),	2.51	(t,	J=7	Hz,	2H,	CH2),	2.25	(s,	6H,	2xCH3).	13C	
NMR	(MeOD)	δ	166.91	(C=O),	144.95	(ArC),	129.34	(ArCH),	128.86	(ArC),	128.18	(ArCH),	57.99	(CH2),	
52.62	(CH2),	51.23	(CH3),	45.55	(CH2),	44.17	(2CH3).	MS	[ESI,	m/z]:	237.1	[M+H].	
Ethyl	4-(((2-(dimethylamino)ethyl)amino)methyl)benzoate	(3c)	yield	92	%.	To	a	solution	of	ethyl	3-
formylbenzoate	(1c;	1.5	mmol)	in	AcOH	(25	mL)	was	added	dropwise	2-dimethylaminoethylamine	(2;	
1.8	mmol).	The	solution	was	stirred	at	room	temperature	for	6h,	then	sodium	triacetoxyborohydride	
(2.4	mmol)	was	added	to	the	mixture	which	was	stirred	at	room	temperature	for	24h.	The	progress	
of	the	reaction	was	monitored	by	TLC.	The	solution	was	then	dried	in	vacuo,	and	the	crude	residue	
was	purified	by	column	chromatography	eluting	with	CH2Cl2/CH3OH	90:10.	1H	NMR	(CDCl3)	7.99	(s,	
1H,	ArH),	7.92	(d,	J=8	Hz,	1H,	ArH),	7.54	(d,	J=8	Hz,	1H,	ArH),	7.38	(t,	J=7.5	Hz,	1H,	ArH),	4.37	(q,	J=7	
Hz,	2H,	CH2),	3.86	(s,	2H,	CH2),	2.72	(t,	J=6	Hz,	2H,	CH2),	2.49	(t,	J=6	Hz,	2H,	CH2),	2.24	(s,	6H,	2CH3).	
13C	NMR	 (CDCl3)	δ	 166.60	 (C=O),	140.36	 (ArC),	 132.69	 (ArCH),	130.58	 (ArC),	 129.22	 (ArCH),	128.42	
(ArCH),	128.23	(ArCH),	60.91	(CH2),	58.56	(CH2),	53.42	(CH2),	46.09	(CH2),	45.13	(2xCH3),	14.47	(CH3).	
MS	[ESI,	m/z]:	calcd	for	C14H22N2O2	[M+H],	251.1754;	found,	251.1754	[M+H],	273.1574	[M+Na+].	
N’,	 N’–dimethyl–N2-(pyridine-2-ylmethyl)ethane-1,2-diamine	 (3d),	 yield	 94%.	 To	 a	 solution	 of	
pyridine-2-carboxaldehyde	 (1d;	 1.5	 mmol)	 in	 MeOH	 (25	 mL)	 was	 added	 dropwise	 2-
dimethylaminoethyl	amine	(2;	1.8	mmol).	The	solution	was	stirred	at	room	temperature	for	4h,	then	
sodium	 triacetoxyborohydride	 (2.4	 mmol)	 was	 added	 to	 the	 mixture	 which	 was	 stirred	 at	 room	
temperature	 for	 24h.	 The	 progress	 of	 the	 reaction	was	monitored	 by	 TLC.	 The	 solution	was	 then	
dried	 in	 vacuo,	 and	 the	 crude	 residue	 was	 purified	 by	 column	 chromatography	 eluting	 with	
CH2Cl2/CH3OH	90:10.	1H-NMR	(CDCl3)	δ	8.55	(s,	1H,	ArH),	7.69	(t,	J=	8	Hz,	1H,	ArH),	7.36	(d,	J=	8	Hz,	
1H,	ArH),	7.23	(t,	J=5	Hz,	1H,	ArH),	3.07	(q,	J=7.5	Hz,	2H,	CH2),	3.01	(t,	J=	6	Hz,	2H,	CH2),	2.87	(t,	J=	6.5	
Hz,	2H,	CH2),	2.48	(s,	6H,	2xCH3),	1.99	(s,	1H,	NH).	MS	[ESI,	m/z]:	271.1	[M+H].	
4-(((4-Chlorobenzyl)(2-(dimethylamino)ethyl)amino)methyl)benzonitrile	(5a)	yield	65	%.	A	mixture	
of	 compound	3a	 (1.22	mmol),	 K2CO3	 (3.65	mmol),	 and	 1-chloro-4-(chloromethyl)benzene	4a	 (2.31	
mmol)	in	anhydrous	tetrahydrofuran	(50	mL)	was	stirred	at	room	temperature	for	24	h.	the	reaction	
mixture	was	evaporated	 in	vacuo	 then	extracted	with	ethyl	acetate	 (2	x	50	mL).	The	organic	 layer	
was	 dried	 then	 evaporated	 and	 purified	 by	 column	 chromatography	 eluting	 with	 CH2Cl2/CH3OH	
90:10.	1H	NMR	(MeOD)	δ	7.69	(d,	J=8.5	Hz,	2H,	ArH),	7.67	(d,	J=8.5	Hz,	2H,	ArH),	7.62	(d,	J=8.5	Hz,	2H,	
ArH),	7.52	(d,	J=8.5	Hz,	2H,	ArH),	4.76	(s,	2H,	CH2),	3.40	(s,	2H,	CH2),	3.62	(t,	J=6.5	Hz,	2H,	CH2),	3.22	
(t,	 J=6.5	 Hz,	 2H,	 CH2),	 3.20	 (s,	 6H,	 2xCH3),	 13C	 NMR	 (MeOD)	δ	 145.91	 (ArC),	 136.67	 (ArC),	 134.46	
(ArCH),	132.32	(ArCH),	128.78	(ArCH),	127.27	(ArCH),	126.41	(ArC),	118.76	(ArC),	110.27	(ArC),	67.59	
(CH2),	63.26	(CH2),	52.51	(CH2),	49.60	(2xCH3),	42.60	(CH2).	MS	[ESI,	m/z]:	calcd	for	C19H22ClN3	[M+H],	
328.1581;	found,	328.1566.	
Methyl	 4-(((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)methyl)	 benzoate	 (5b)	 yield	 57	 %.	 A	
mixture	of	compound	3b	(1.22	mmol),	K2CO3	(3.65	mmol),	and	1-chloro-4	(chloromethyl)benzene	4a	
(2.31	 mmol)	 in	 anhydrous	 THF	 (50	 mL)	 was	 stirred	 at	 room	 temperature	 for	 24	 h.	 the	 reaction	
mixture	was	evaporated	 in	vacuo	 then	extracted	with	ethyl	acetate	 (2	x	50	mL).	The	organic	 layer	
was	 dried	 then	 evaporated	 and	 purified	 by	 column	 chromatography	 eluting	 with	 CH2Cl2/CH3OH	
90:10.	1H	NMR	(CDCl3)	δ	8.01	(d,	J=8.5	Hz,	2H,	ArH),	7.45	(d,	J=8.5	Hz,	2H,	ArH),	7.31	(s,	2H,	ArH),	7.30	
(d,	J=9	Hz,	2H,	ArH),	3.93	(s,	3H,	CH3),	3.66	(s,	2H,	CH2),	3.59	(s,	2H,	CH2),	2.59	(m,	2H,	CH2),	2.48	(m,	
2H,	 CH2),	 2.20	 (s,	 6H,	 2xCH3).	 13C	NMR	 (CDCl3)	δ	 167.07	 (C=O),	 145.04	 (ArC),	 137.83	 (ArC),	 132.69	
(ArC),	130.03	(ArCH),	129.62	(ArCH),	128.95	(ArC),	128.58	(ArCH),	128.42	(ArCH),	58.52	(CH2),	58.20	
(CH2),	 57.48	 (CH2),	 52.05	 (CH3),	 51.53	 (CH2),	 45.63	 (2xCH3).	 MS	 [ESI,	 m/z]:	 calcd	 for	 C20H25ClN2O2	
[M+H],	361.1677;	found,	361.1679	[M+H],	383.1497	[M+Na].	
Ethyl	 3-(((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)methyl)	 benzoate	 (5c)	 yield	 61	 %.	 A	
mixture	of	compound	3c	(1.22	mmol),	K2CO3	(3.65	mmol),	and	1-chloro-4	(chloromethyl)benzene	4a	
(2.31	mmol)	 in	anhydrous	 tetrahydrofuran	 (50	mL)	was	 stirred	at	 room	temperature	 for	24	h.	 the	
reaction	mixture	was	evaporated	in	vacuo	then	extracted	with	ethyl	acetate	(2	x	50	mL).	The	organic	
layer	was	dried	then	evaporated	and	purified	by	column	chromatography	eluting	with	CH2Cl2/CH3OH	
90:10.	1H	NMR	(CDCl3)	δ	8.03-8.01	(m,	1H,	ArH),	7.94	(dd,	J=8,1.5	Hz,	1H,	ArH),	7.58	(ddd,	J=7.5,	2,	
1.5	Hz,	1H,	ArH),	7.41	(d,	J=8	Hz,	1H,	ArH),	7.32-7.28	(m,	4H,	ArH),	4.41	(q,	J=7	Hz,	2H,	CH2),	3.66	(s,	
2H,	CH2),	3.59	(s,	2H,	CH2),	2.63	(t,	J=8	Hz,	2H,	CH2),	2.51	(t,	J=8	Hz,	2H,	CH2),	2.22	(s,	6H,	2CH3),	1.43	
(t,	 J=7.5	Hz,	 3H,	 CH3).	 13C	NMR	 (CDCl3)	δ	 166.70	 (C=O),	 139.73	 (ArC),	 137.88	 (ArC),	 133.21	 (ArCH),	
132.67	 (ArC),	 130.50	 (ArC),	 130.07	 (ArCH),	 129.78	 (ArCH),	 128.42	 (ArCH),	 128.35	 (ArCH),	 128.30	
(ArCH),	60.98	(CH2),	58.39	(CH2),	58.08	(CH2),	57.43	(CH2),	51.31	(CH2),	45.59	(2CH3),	14.36	(CH3).	MS	
[ESI,	m/z]:	calcd	for	C21H27ClN2O2	[M+H],	375.1834;	found,	375.1838	[M+H],	397.1650	[M+Na].	
N1-(4-chlorobenzyl)-N2,	 N2-dimethyl-N1-(pyridin-2-ylmethyl)ethane-1,2-diamine	 (5d)	 yield	69	%.	 A	
mixture	of	compound	3d	(1.22	mmol),	K2CO3	(3.65	mmol),	and	1-chloro-4-(chloromethyl)benzene	4a	
(2.31	mmol)	 in	anhydrous	 tetrahydrofuran	 (50	mL)	was	 stirred	at	 room	temperature	 for	24	h.	 the	
reaction	mixture	was	evaporated	in	vacuo	then	extracted	with	ethyl	acetate	(2	x	50	mL).	The	organic	
layer	was	dried	then	evaporated	and	purified	by	column	chromatography	eluting	with	CH2Cl2/CH3OH	
90:10.	1H	NMR	(CDCl3)	δ	8.40	(ddd,	J=	5,	2,1	Hz,	1H,	ArH),	7.67	(td,	J=	8,	2	Hz,	1H,	ArH),	7.67	(d,	J=	7.5	
Hz,	1H,	ArH),	7.33	 (d,	 J=	8.5	Hz,	2H,	ArH),	7.29	 (d,	 J=	9	Hz,	2H,	ArH),	7.16	 (ddd,	 J=	7.5,	5,1	Hz,	1H,	
ArH),	3.79	(s,	2H,	CH2),	3.65	(s,	2H,	CH2),	2.63	(dd,	J=	9,	7.5	Hz,	2H,	CH2),	2.47	(dd,	J=	9,	7.5	Hz,	2H,	
CH2),	2.18	(s,	6H,	2CH3).	13C	NMR	(CDCl3)	δ	159.91	(ArC),	148.95	(ArCH),	137.90	(ArC),	136.44	(ArCH),	
132.58	(ArC),	130.10	(ArCH),	128.37	(ArCH),	122.82	(ArCH),	121.97	(ArCH),	60.50	(CH2),	58.38	(CH2),	
57.53	 (CH2),	 51.93	 (CH2),	 45.83	 (CH3).	 [ESI,	 m/z]:	 304.1576	 [M+H],	 326.1396	 [M+Na].	 calcd	 for	
C17H22ClN3	[M+H],	304.1575;	found,	304.1576.	
N-(4-(((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)methyl)benzylidyne)-1-(4-chlorophenyl)	
methanaminium	(6)	yield	21	%.	 1H	NMR	 (CDCl3)	δ	7.63	 (d,	 J=8.5	Hz,	2H,	ArH),	7.48	 (d,	 J=8	Hz,	2H,	
ArH),	7.45	(d,	J=8.5	Hz,	2H,	ArH),	7.35	(d,	J=8.5	Hz,	2H,	ArH),	7.30	(d,	J=8.5	Hz,	2H,	ArH),	7.21	(d,	J=8.5	
Hz,	2H,	ArH),	5.04	(s,	2H,	CH2),	3.99	(t,	J=6	Hz,	2H,	CH2),	3.76	(s,	2H,	CH2),	3.56	(s,	2H,	CH2),	3.09	(s,	
6H,	 2xCH3),	 2.93	 (t,	 J=6	Hz,	 2H,	 CH2).	 13C	NMR	 (CDCl3)	δ	 143.45	 (ArC),	 137.32	 (ArC),	 135.97	 (ArC),	
134.50	 (ArCH),	 133.75	 (ArC),	 132.44	 (ArCH),	 130.69	 (ArCH),	 129.89	 (ArCH),	 129.46	 (ArCH),	 128.92	
(ArCH),	125.59	(ArC),	118.56	(ArC),	111.52	(ArC),	67.26	(CH2),	60.65	(CH2),	58.31	(CH2),	57.94	(CH2),	
49.33	(2xCH3),	47.26	(CH2).	MS	[ESI,	m/z]:	calcd	for	C26H28Cl2N3	[M+],	452.1660,	found	452.1647.	
3-(2-(Dimethylamino)ethylamino)isoindolin-1-one	 (8)	 yield	 93	 %.	 To	 a	 solution	 of	 2-formyl	
benzonitrile	(7;	1.5	mmol)	in	MeOH	(25	mL)	was	added	dropwise	2-dimethylaminoethylamine	(2;	1.8	
mmol).	 The	 solution	 was	 stirred	 at	 room	 temperature	 for	 4h,	 sodium	 triacetoxyborohydride	 (2.4	
mmol)	 was	 added	 to	 the	mixture	 and	 stirred	 at	 room	 temperature	 for	 24h.	 The	 progress	 of	 the	
reaction	was	monitored	by	TLC.	 The	 solution	was	 then	dried	 in	 vacuo,	 and	 the	 crude	 residue	was	
purified	by	column	chromatography	eluting	with	CH2Cl2/CH3OH	90:10.	1H	NMR	(CDCl3)	δ	7.78,	7.76	
(2t,	J=1	Hz,	1H,	ArH),	7.70-7.69	(2m,	1H,	ArH),	7.67	(ddd,	J=7.5,	7,	1	Hz,	1H,	ArH),	7.55	(m,	1H,	ArH),	
5.53	(s,	1H,	CH),	3.34,	3.33	(2t,	J=1.5	Hz,	1H,	CH2),	2.77,	2.75	(2t,	J=6.5	Hz,	1H,	CH2),	2.62,	2.59	(2t,	
J=6.5	Hz,	1H,	CH2),	2.46,	2.45	 (2t,	 J=6.5	Hz,	2H,	CH2),	2.25	 (s,	6H,	2CH3);	 13C	NMR	 (CDCl3)	δ	170.00	
(C=O),	145.57	(ArC),	132.58	(ArC),	132.03	(ArCH),	129.09	(ArCH),	123.62	(ArCH),	123.41	(ArCH),	70.68	
(CH),	60.07	(CH2),	45.28	(2xCH3),	41.90	(CH2).	MS	[ESI,	m/z]:	220.16	[M+H],	242.14	[M+Na].	
N-(4-chlorobenzyl)pyridin-2-amine	(11a)	yield	96	%.	The	solution	of	pyridin-2-amine	(9a;	1.5	mmol)	
and	4-chlorobenzaldehyde	(10a;	1.5	mmol)	in	AcOH	(10	mL)	was	stirred	at	room	temperature	for	4h,	
sodium	 triacetoxyborohydride	 (2.4	 mmol)	 was	 added	 to	 the	 mixture	 and	 stirred	 at	 room	
temperature	for	24h.	Water	(10	mL)	was	added	and	the	mixture	neutralized	using	NaHCO3	(sat.	aq.,	
10	mL).	 The	 organic	 layer	was	 extracted	with	DCM	 (2	 ×	 10	mL),	 dried,	 evaporated	 and	 the	 crude	
residue	was	purified	by	column	chromatography	eluting	with	CH2Cl2/CH3OH	90:10.1H	NMR	(CDCl3)	δ	
8.00	(dd,	J=	5,	2	Hz,	1H,	ArH),	7.33	(ddd,	J=	8.5,	7,	2	Hz,	1H,	ArH),	7.15-7.25	(m,	4H,	ArH),	6.52	(ddd,	
J=	7,	 5,	 1	Hz,	 1H,	ArH),	 6.27	 (d,	 J=	8.5	Hz,	 1H,	ArH),	 5.23	 (bs,	 1H,	NH),	 4.40	 (s,	 2H,	 CH2).	 13C	NMR	
(CDCl3)	 δ	 158.37	 (ArC),	 147.76	 (ArCH),	 137.81	 (ArCH),	 137.72	 (ArC),	 132.93	 (ArC),	 128.76	 (ArCH),	
128.63	(ArCH),	113.30	(ArCH),	106.91	(ArCH),	45.57	(CH2).	[ESI,	m/z]:	219.1	[M+H],	241.1	[M+Na].	
General	method	for	the	preparation	of	intermediates	11	(b-h)	and	14	
The	 solution	 of	 the	 corresponding	 aniline	 derivatives	 (9b-h;	 1.5	mmol)	 and	 4-chlorobenzaldehyde	
(10a)	 or	 4-fluorobenzaldehyde	 (10b);	 (1.5	 mmol)	 in	 dichloroethanol	 (DCE,	 10	 mL)	 was	 stirred	 at	
reflux	temperature	for	8h.	After	cooling,	sodium	triacetoxyborohydride	(2.4	mmol)	was	added	to	the	
mixture	and	stirred	at	room	temperature	for	24h.	Water	(10	mL)	was	added.	The	organic	layer	was	
extracted	 with	 DCM	 (2×10mL),	 dried,	 evaporated	 and	 the	 crude	 residue	 was	 purified	 by	 column	
chromatography	eluting	with	n-hexane/EtOAc	90:10.	
Methyl	4-((4-chlorobenzyl)amino)-2-hydroxybenzoate	(11b)	yield	97	%.	1H	NMR	(CDCl3)	δ	10.99	(s,	
1H,	OH),	7.63	(d,	J	=	9	Hz,	1H,	ArH),	7.34	(d,	J	=	8.5	Hz,	2H,	ArH),	7.29	(d,	J	=	8.5	Hz,	2H,	ArH),	6.14	(dd,	
J	=	8.5,	2	Hz,	1H,	ArH),	6.11	(d,	J	=	2	Hz,	1H,	ArH),	4.54	(bs,	1H,	NH),	4.37	(s,	2H,	CH2),	3.90	(s,	3H,	
CH3);	 13C	 NMR	 (CDCl3)	 δ	 170.49	 (C=O),	 163.77	 (ArC),	 153.86	 (ArC),	 136.68	 (ArC),	 133.34	 (ArCH),	
131.29	(ArCH),	128.95	(ArCH),	128.62	(ArCH),	105.63	(ArCH),	102.38	(ArC),	98.20	(ArCH),	51.64	(CH3),	
46.85	(CH2).	MS	[ESI,	m/z]:	292.1	[M+H].	
Methyl	4-((4-chlorobenzyl)amino)-2-hydroxybenzoate	(11c)	yield	98	%.	1H	NMR	(CDCl3)	δ	10.21	(s,	
OH),	 7.36-7.30	 (m,	4H,	ArH),	 7.08	 (dd,	 J	 =	2.5,	1	Hz,	1H,	ArH),	 6.89-6.86	 (m,	2H,	ArH),	 4.29	 (s,	 2H,	
CH2),	 3.94	 (s,	 3H,	 CH3);	 13C	NMR	 (CDCl3)	δ	170.48	 (C=O),	 154.35	 (ArC),	 140.56	 (ArC),	 137.92	 (ArC),	
132.87	 (ArC),	 128.83	 (ArCH),	 128.70	 (ArCH),	 122.76	 (ArCH),	 118.20	 (ArCH),	 112.21	 (ArC),	 111.75	
(ArCH),	52.17	(CH3),	48.33	(CH2).	MS	[ESI,	m/z]:	292.1	[M+H].	
Methyl	4-((4-chlorobenzyl)amino)-2-methoxybenzoate	(11d)	yield	85	%.	1H	NMR	(CDCl3)	δ	7.78	(d,	
J=8.5	Hz,	1H,	ArH),	7.35	 (d,	 J=8.5	Hz,	2H,	ArH),	7.31	 (d,	 J=9	Hz,	2H,	ArH),	7.21	 (dd,	 J=8.5,	2	Hz,	1H,	
ArH),	6.13	(d,	J=2	Hz,	1H,	ArH),	4.51	(t,	J=5.5	Hz,	1H,	NH),	4.39	(d,	J=5.5	Hz,	2H,	CH2),	3.85	(s,	3H,	CH3),	
3.84	(s,	3H,	CH3);	13C	NMR	(CDCl3)	δ	166.22	(C=O),	161.79	(ArC),	152.66	(ArC),	136.86	(ArC),	134.17	
(ArCH),	133.33	(ArC),	128.95	(ArCH),	128.67	(ArCH),	108.43	(ArC),	104.40	(ArCH),	95.81	(ArCH),	55.76	
(CH3),	51.41	(CH3),	47.12	(CH2).	MS	[ESI,	m/z]:	306.1	[M+H],	328.1	[M+Na].		
4-((4-Chlorobenzyl)amino)-2-methoxybenzoic	acid	(11e)	yield	96	%.1H	NMR	(CDCl3)	δ	10.25	(bs,	1H,	
COOH),	7.97	(d,	J=8.5	Hz,	1H,	ArH),	7.36	(d,	J=8.5	Hz,	2H,	ArH),	7.30	(d,	J=8.5	Hz,	2H,	ArH),	6.34	(dd,	
J=8.5,	2	Hz,	1H,	ArH),	6.14	(d,	J=2.5	Hz,	1H,	ArH),	4.81	(bs,	1H,	NH),	4.41	(s,	2H,	CH2),	3.96	(s,	3H,	CH3);	
13C	 NMR	 (CDCl3)	 δ	 165.87	 (C=O),	 159.98	 (ArC),	 153.52	 (ArC),	 136.41	 (ArC),	 135.40	 (ArCH),	 133.49	
(ArC),	 129.05	 (ArCH),	128.60	 (ArCH),	106.47	 (ArCH),	106.41	 (ArC),	 94.64	 (ArCH),	56.26	 (CH3),	47.01	
(CH2).	MS	[ESI,	m/z]:	292.1	[M+H],	314.1	[M+Na].	
4-(4-Chlorobenzylamino)-2-hydroxybenzoic	 acid	 (11f)	yield	81	%.	 1H	NMR	 (DMSO-d6)	δ	 12.87	 (bs,	
1H,	COOH),	11.44	(bs,	1H,	OH),	7.45	(d,	J	=	9	Hz,	1H,	ArH),	7.40	(d,	J	=	8.5	Hz,	2H,	ArH),	7.35	(d,	J	=	8.5	
Hz,	2H,	ArH),	7.20	(t,	J	=	6	Hz,	1H,	NH),	6.19	(dd,	J	=	8.5,	2	Hz,	1H,	ArH),	6.93	(d,	J	=2	Hz,	1H,	ArH),	4.32	
(d,	J	=	6	Hz,	2H,	CH2);	13C	NMR	(DMSO-d6)	δ	172.55	(C=O),	163.95	(ArC),	155.19	(ArC),	138.91	(ArC),	
131.80	 (ArC),	 131.59	 (ArCH),	 129.41	 (ArCH),	 128.82	 (ArCH),	 106.05	 (ArCH),	 100.90	 (ArC),	 97.32	
(ArCH),	45.46	(CH2).	MS	[ESI,	m/z]:	278.1	[M+H],	300.0	[M+Na].	anal.	calcd	for	C14H12ClNO3:	C,	60.55;	
H,	4.36;	N,	5.04.	Found:	C,	60.18;	H,	4.39;	N,	4.95.	
5-((4-Chlorobenzyl)amino)-2-methoxybenzoic	acid	(11g)	yield	60	%.	1H	NMR	(CDCl3)	δ	10.90	(bs,	1H,	
COOH),	7.48	(d,	J=	3	Hz,	1H,	ArH),	7.33	(d,	J=	8.5	Hz,	2H,	ArH),	7.30	(d,	J=	8.5	Hz,	2H,	ArH),	6.92	(d,	J=	
9	Hz,	1H,	ArH),	6.79	(dd,	J=	9	Hz,	3	Hz,	1H,	ArH),	4.34	(s,	2H,	CH2),	4.01	(s,	3H,	CH3).	13C	NMR	(CDCl3)	δ	
165.55	(C=O),	150.55	(ArC),	142.80	(ArC),	137.25	(ArC),	133.15	(ArC),	128.84	(ArCH),	128.75	(ArCH),	
119.24	(ArCH),	118.19	(ArC),	117.05	(ArCH),	113.30	(ArCH),	57.22	(CH3),	48.00	(CH2).	MS	[AP,	m/z]:	
292.1	[M+H].	
Methyl	4-((4-chlorobenzyl)amino)benzoate	(11h)	yield	95	%.	1H	NMR	(CDCl3)	δ	7.88	(d,	J=	9	Hz,	2H,	
ArH),	7.34	(d,	J=	9	Hz,	2H,	ArH),	7.30	(d,	J=	9	Hz,	2H,	ArH),	6.59	(d,	J=	9	Hz,	2H,	ArH),	4.39	(s,	2H,	CH2),	
3.87	 (s,	3H,	CH3).13C	NMR	(CDCl3)	δ	167.21	 (C=O),	151.46	 (ArC),	136.93	 (ArC),	133.27	 (ArC),	133.27	
(ArCH),	129.48	(ArCH),	129.22	(ArCH),	119.03	(ArC),	111.74	(ArCH),	51.59	(CH3),	47.01	(CH2).	MS	[ESI,	
m/z]:	274.1	[M-H].	
General	method	for	the	preparation	of	intermediates	11i-k	
The	 solution	 of	 the	 corresponding	 aniline	 (9i-k;	 1.5	 mmol)	 and	 4-chlorobenzaldehyde	 or	 4-
fluorobenzaldehyde	 (10a;	 1.5	 mmol)	 in	 AcOH	 (10	 mL)	 was	 stirred	 at	 room	 temperature	 for	 4h,	
sodium	 triacetoxyborohydride	 (2.4	 mmol)	 was	 added	 to	 the	 mixture	 and	 stirred	 at	 room	
temperature	for	24h.	Water	(10	mL)	was	added	and	the	mixture	neutralized	using	NaHCO3	(sat.	aq.,	
10	mL).	The	organic	layer	was	extracted	with	DCM	(2	×	10	mL),	dried	and	evaporated.	
2-((4-Chlorobenzyl)amino)benzonitrile	 (11i)	 yield	 95	 %.	 1H	 NMR	 (CDCl3)	 δ	 7.44	 (d,	 J=	 7.5	 Hz,	 1H,	
ArH),	7.34-7.37	(m,	3H,	ArH),	7.30	(d,	J=	9	Hz,	2H,	ArH),	6.73	(t,	J=	6.5	Hz,	1H,	ArH),	6.59	(d,	J=	8.5	Hz,	
1H,	ArH),	5.05	(t,	J=	6	Hz,	1H,	NH),	4.44	(d,	J=	6	Hz,	2H,	CH2).13C	NMR	(CDCl3)	δ	149.80	(CN),	136.28	
(ArCH),	 134.30	 (ArC),	 133.42	 (ArC),	 132.81	 (ArCH),	 129.05	 (ArCH),	 128.41	 (ArCH),	 117.77	 (ArC),	
117.19	(ArCH),	111.04	(ArCH),	96.18	(ArC),	46.84	(CH2).	MS	[EI,	m/z]:	242.061.	
3-((4-Chlorobenzyl)amino)benzonitrile	(11j)	yield	97	%.	1H	NMR	(CDCl3)	δ	7.36	(d,	J=8.5	Hz,	2H,	ArH),	
7.30	(d,	J=8.5	Hz,	2H,	ArH),	7.29	(td,	J=7.5,	1	Hz,	1H,	ArH),	7.01	(dt,	J=	7.5,	1.5	Hz,	1H,	ArH),	6.81	(m,	
1H,	 ArH),	 4.34	 (d,	 J=5	 Hz,	 2H,	 CH2);	 13C	 NMR	 (CDCl3)	 δ	 147.84	 (ArC),	 136.56	 (ArC),	 133.41	 (ArC),	
130.00	 (ArCH),	 129.01	 (ArCH),	 128.62	 (ArCH),	 121.38	 (ArCH),	 119.31	 (CN),	 117.41	 (ArCH),	 115.26	
(ArCH),	113.07	(ArC),	47.31	(CH2).	MS	[ESI,	m/z]:	242.0610	[M+H].	
4-((4-Chlorobenzyl)amino)benzonitrile	(11k)	yield	96	%.	1H	NMR	(CDCl3)	δ	7.45	(d,	J=9	Hz,	2H,	ArH),	
7.36	(d,	J=8.5	Hz,	2H,	ArH),	7.29	(d,	J=8.5	Hz,	2H,	ArH),	6.60	(d,	J=9	Hz,	2H,	ArH),	4.63	(bs,	1H,	NH),	
4.39	 (d,	 J=5	Hz,	2H,	CH2),	 4.39	 (d,	 J=5.5	Hz,	2H,	CH2),	 3.87	 (s,	 3H,	CH3),	 3.84	 (s,	 3H,	CH3);	 13C	NMR	
(CDCl3)	 δ	 150.89	 (ArC),	 136.39	 (ArC),	 133.76	 (ArCH),	 133.44	 (ArC),	 129.35	 (ArCH),	 128.56	 (ArCH),	
120.29	(CN),	112.51	(ArCH),	99.42	(ArC),	46.83	(CH2).	MS	[ESI,	m/z]:	242.06	[M+H].	
3-(4-Fluorobenzylamino)benzonitrile	 (11l)	yield	57	%.	 The	 solution	of	 3-aminobenzonitrile	 (9l;	 1.5	
mmol)	 and	 4-fluorobenzaldehyde	 (10b;	 1.5	 mmol)	 in	 MeOH	 (10	 mL)	 was	 stirred	 at	 room	
temperature	for	7h,	sodium	triacetoxyborohydride	(2.4	mmol)	was	added	to	the	mixture	and	stirred	
at	 room	 temperature	 for	 24h.	 Water	 (10	 mL)	 was	 added	 to	 the	 mixture	 and	 the	 product	 was	
extracted	using	ethyl	acetate	and	water	and	recrystallised	from	methanol.	1H-NMR	(CDCl3)	δ7.22	(dd,	
J=9,	5	Hz,	2H,	ArH),	7.12	(dd,	J=	9,	7.5	Hz,	1H,	ArH),	6.95	(t,	J=	9	Hz,	2H,	ArH),	6.87	(d,	J=	8	Hz,	1H,	
ArH),	 6.72-6.70	 (m,	 2H,	 ArH),	 4.21	 (s,	 2H,	 CH2),	 4.37	 (s,	 1H,	 NH).	 MS	 [ESI,	 m/z]:	 [M+H]	 227.1	 &	
[M+Na]	249.1.	
General	method	for	the	preparation	of	compounds	13a-l	
The	mixture	of	the	corresponding	secondary	amine	(11a-l;	1.5	mmol),	dimethylaminoacetyl	chloride	
hydrochloride	 (12;	 1.6	mmol)	 and	 potassium	 carbonate	 (3.2	mmol)	 in	 THF	 (10	mL)	was	 stirred	 at	
room	temperature	for	24h.	The	mixture	was	extracted	with	EtOAc	(3	×	20	mL),	the	organic	layer	was	
dried,	 evaporated	 and	 the	 crude	 residue	 was	 purified	 by	 column	 chromatography	 eluting	 with;	
CH2Cl2/CH3OH	90:10.	
N-(4-chlorobenzyl)-2-(dimethylamino)-N-(pyridin-2-yl)	acetamide	(13a)	yield	89	%.	1H	NMR	(CDCl3)	
δ	8.40	(dd,	J=	5.0,	1.0	Hz,	1H,	ArH),	7.59	(ddd,	J=	8.0,	7.5,	2	Hz,	1H,	ArH),	7.15	(d,	J=	8.5	Hz,	2H,	ArH),	
7.13-7.09	 (m,	 3H,	 ArH),	 7.08-7.00	 (m,	 1H,	 ArH),	 5.00	 (s,	 2H,	 CH2),	 3.06	 (s,	 2H,	 CH2),	 2.19	 (s,	 6H,	
2xCH3).13C	NMR	 (CDCl3)	 δ	 170.09	 (C=O),	 154.60	 (ArC),	 149.16	 (ArCH),	 138.14	 (ArCH),	 136.12	 (ArC),	
133.07	(ArC),	129.43	(ArCH),	128.76	(ArCH),	122.19	(ArCH),	121.27	(ArCH),	61.59	(CH2),	50.52	(CH2),	
45.30	(2xCH3).	[ESI,	m/z]:	304.1212	[M+H],	326.1030	[M+Na].	calcd	for	C16H18ClN3O	[M+H],	304.1211;	
found,	304.1212.	
Methyl	4-(N-(4-chlorobenzyl)-2-(dimethylamino)acetamido)-2-hydroxy	benzoate	 (13b)	yield	88	%.	
1H	NMR	(CDCl3)	δ	10.86	(bs,	1H,	OH),	7.82	(d,	J	=	8.5	Hz,	1H,	ArH),	7.25	(d,	J	=	8.5	Hz,	2H,	ArH),	7.16	
(d,	J	=	8.5	Hz,	2H,	ArH),	6.71	(d,	J	=	2	Hz,	1H,	ArH),	6.53	(dd,	J	=	8.5,	2	Hz,	1H,	ArH),	4.88	(s,	2H,	CH2),	
3.98	(s,	3H,	CH3),	2.97	(s,	2H,	CH2),	2.28	(s,	6H,	2xCH3);	13C	NMR	(CDCl3)	δ	169.84	(C=O),	169.32	(C=O),	
162.36	(ArC),	148.09	(ArC),	135.60	(ArC),	133.45	(ArC),	131.11	(ArCH),	130.05	(ArCH),	128.67	(ArCH),	
119.10	 (ArCH),	 116.90	 (ArCH),	 111.99	 (ArC),	 60.90	 (CH2),	 52.56	 (OCH3),	 54.10	 (CH2),	 45.56	 (2xCH3).	
MS	[ESI,	m/z]:	calcd	for	C19H21ClN2O4	[M+H],	377.1268;	found,	377.1266.	
Methyl	5-(N-(4-chlorobenzyl)-2-(dimethylamino)acetamido)-2-hydroxy	benzoate	(13c)	yield	92	%.	
1H	NMR	(CDCl3)	δ	10.83	(bs,	1H,	OH),	7.47	(d,	J	=	2.5	Hz,	1H,	ArH),	7.26	(d,	J	=	8.5	Hz,	2H,	ArH),	7.15	
(d,	J	=	8.5	Hz,	2H,	ArH),	7.01	(dd,	J	=	9.0,	2.5	Hz,	1H,	ArH),	6.94	(d,	J	=	9	Hz,	1H,	ArH),	4.82	(s,	2H,	CH2),	
3.97	(s,	3H,	CH3),	2.85	(s,	2H,	CH2),	2.26	(s,	6H,	2CH3);	13C	NMR	(CDCl3)	δ	169.79	(C=O),	169.67	(C=O),	
161.15	(ArC),	136.00	(ArCH),	135.70	(ArC),	133.45	(ArC),	132.49	(ArC),	130.45	(ArCH),	129.53	(ArCH),	
128.65	 (ArCH),	 118.92	 (ArCH),	 112.90	 (ArC),	 60.70	 (CH2),	 52.67	 (OCH3),	 52.42	 (CH2),	 45.61	 (2xCH3).	
MS	[ESI,	m/z]:	calcd	for	C19H21ClN2O4	[M+H],	377.1268;	found,	377.1266.	
Methyl	4-(N-(4-chlorobenzyl)-2-(dimethylamino)acetamido)-2-methoxy	benzoate	(13d)	yield	95	%.	
1H	NMR	(CDCl3)	δ	7.78	(d,	J	=	8.5	Hz,	1H,	ArH),	7.27	(d,	J	=	8.5	Hz,	2H,	ArH),	7.17	(d,	J	=	8.5	Hz,	2H,	
ArH),	6.65	(dd,	J	=	8.5,	2	Hz,	1H,	ArH),	6.55	(s,	1H,	ArH),	4.87	(s,	2H,	CH2),	3.92	(s,	3H,	CH3),	3.78	(s,	
3H,	CH3),	2.91	(s,	2H,	CH2),	2.27	(s,	6H,	2xCH3);	13C	NMR	(CDCl3)	δ	169.31	(C=O),	165.90	(C=O),	159.75	
(ArC),	146.06	(ArC),	135.76	(ArC),	133.57	(ArC),	132.70	(ArCH),	130.38	(ArCH),	128.67	(ArCH),	119.88	
(ArCH),	114.09	(ArC),	112.20	(ArCH),	60.87	(CH2),	56.15	(CH3),	52.27	(CH3),	52.20	(CH2),	45.68	(2xCH3).	
MS	[ESI,	m/z]:	calcd	for	C20H23ClN2O4	[M+H],	391.1425;	found,	391.1418.	
4-(N-(4-chlorobenzyl)-2-(dimethylamino)acetamido)-2-methoxybenzoic	 acid	 (13e)	 yield	 79	 %	 1H	
NMR	(CDCl3)	δ	7.91	(d,	J	=	5.5	Hz,	1H,	ArH),	7.17	(d,	J	=	9	Hz,	2H,	ArH),	7.06	(d,	J	=	9	Hz,	2H,	ArH),	6.66	
(dd,	J	=	5.5,	1	Hz,	1H,	ArH),	6.52	(s,	1H,	ArH),	4.78	(s,	2H,	CH2),	3.75	(s,	3H,	CH3),	2.97	(s,	2H,	CH2),	2.90	
(s,	 6H,	 2xCH3);	 13C	 NMR	 (CDCl3)	δ	 168.91	 (C=O),	 168.83	 (C=O),	 159.71	 (ArC),	 142.67	 (ArC),	 137.93	
(ArC),	 135.63	 (ArC),	 133.35	 (ArC),	 132.70	 (ArCH),	 131.44	 (ArCH),	 130.63	 (ArCH),	 122.06	 (ArCH),	
113.67	 (ArCH),	 61.17	 (CH2),	 57.19	 (OCH3),	 54.20	 (CH2),	 46.07	 (2xCH3).	 MS	 [ESI,	 m/z]:	 calcd	 for	
C19H21ClN2O4	[M+H],	377.1268;	found,	377.1266.	
4-(N-(4-chlorobenzyl)-2-(dimethylamino)acetamido)-2-hydroxybenzoic	 acid	 (13f)	 yield	 61	 %	 1H	
NMR	(DMSO-d6)	δ	7.65	(d,	 J	=	8	Hz,	1H,	ArH),	7.38	(d,	 J	=	8.5	Hz,	2H,	ArH),	7.25	(d,	 J	=	8.5	Hz,	2H,	
ArH),	6.48	(d,	J	=	2	Hz,	1H,	ArH),	6.41	(dd,	J	=	8,	1.5	Hz,	1H,	ArH),	4.86	(s,	2H),	3.73	(s,	2H),	2.62	(s,	
6H);	 13C	 NMR	 (DMSO-d6)	 δ	 170.79	 (C=O),	 165.90	 (C=O),	 164.79	 (ArC),	 142.76	 (ArC),	 136.43	 (ArC),	
132.36	 (ArC),	 131.33	 (ArCH),	 130.38	 (ArCH),	 128.79	 (ArCH),	 120.81	 (ArC),	 115.75	 (ArCH),	 115.34	
(ArCH),	 58.33	 (CH2),	 51.93	 (CH2),	 44.28	 (2xCH3).	 MS	 [ESI,	 m/z]:	 calcd	 for	 C18H19ClN2O4	 [M+H],	
363.1123;	found,	363.1112.	
5-(N-(4-chlorobenzyl)-2-(dimethylamino)acetamido)-2-methoxybenzoic	 acid	 (13g)	 yield	 78	 %	 1H	
NMR	(MeOD-d4)	δ	7.76	(s,	1H,	ArH),	7.48	(d,	J=	8.5	Hz,	2H,	ArH),	7.42	(d,	J=	9	Hz,	1H,	ArH),	7.39	(d,	J=	
8.5	Hz,	2H,	ArH),	7.34	(d,	J=	9	Hz,	1H,	ArH),	5.09	(s,	2H,	CH2),	4.08	(s,	3H,	CH3),	4.06	(s,	2H,	CH2),	3.07	
(s,	6H,	2xCH3).13C	NMR	(MeOD-d4)	δ	168.32	(C=O),	164.38	(C=O),	158.93	(ArC),	134.89	(ArC),	133.38	
(ArC),	 133.18	 (ArCH),	 130.86	 (ArCH),	 130.64	 (ArC),	 130.29	 (ArCH),	 128.37	 (ArCH),	 122.85	 (ArC),	
113.33	 (ArCH),	 57.94	 (CH2),	 55.41	 (OCH3),	 52.15	 (CH2),	 43.25	 (CH3).	 MS	 [ESI,	 m/z]:	 calcd	 for	
C19H21ClN2O4	[M+H],	377.1268;	found,	377.1279.	
Methyl	 4-(N-(4-chlorobenzyl)-2-(dimethylamino)acetamido)benzoate	 (13h)	 yield	 69	 %	 1H	 NMR	
(CDCl3)	δ	8.03	(d,	J=	8.5	Hz,	2H,	ArH),	7.25	(d,	J=	8.5	Hz,	2H,	ArH),	7.14	(d,	J=	8.5	Hz,	2H,	ArH),	7.08	(d,	
J=	8.5	Hz,	2H,	ArH),	4.89	(s,	2H,	CH2),	3.94	(s,	3H,	CH3),	2.89	(s,	2H,	CH2),	2.25	(s,	6H,	2xCH3).13C	NMR	
(CDCl3)	δ	169.36	(C=O),	166.13	(C=O),	145.64	(ArC),	135.56	(ArC),	133.52	(ArC),	130.99	(ArCH),	130.86	
(ArCH),	 130.21	 (ArC),	 128.70	 (ArCH),	 118.56	 (ArCH),	 63.67	 (CH2),	 52.38	 (CH3),	 52.31	 (CH2),	 45.54	
(2xCH3).	MS	[ESI,	m/z]:	calcd	for	C19H21ClN2O3	[M+H],	361.1319;	found,	361.1.	
N-(4-chlorobenzyl)-N-(2-cyanophenyl)-2-(dimethylamino)acetamide	 (13i)	 yield	 71	 %	 1H	 NMR	
(CDCl3)	δ	7.74	(d,	J=	8	Hz,	1H,	ArH),	7.54	(t,	J=	7.5	Hz,	1H,	ArH),	7.46	(t,	J=	7.5	Hz,	1H,	ArH),	7.24	(d,	J=	
8.5	Hz,	2H,	ArH),	7.14	(d,	J=	8.5	Hz,	2H,	ArH),	6.92	(d,	J=	8	Hz,	1H,	ArH),	4.48	(d,	J=	14.5	Hz,	1H,	CH),	
4.38	 (d,	 J=	14.5	Hz,	1H,	CH),	2.87	 (s,	2H,	CH2),	2.20	 (s,	6H,	2xCH3).13C	NMR	(CDCl3)	δ	169.41	 (C=O),	
143.86	(CN),	134.84	(ArC),	133.84	(ArCH),	133.80	(ArC),	133.61	(ArCH),	130.74	(ArCH),	130.35	(ArCH),	
128.72	 (2ArCH),	115.93	 (ArC),	 113.57	 (ArC),	 61.28	 (CH2),	51.98	 (CH2),	45.29	 (2xCH3).	MS	 [ESI,	m/z]:	
calcd	for	C18H18ClN3O	[M+H],	328.1212;	found,	328.1217.	
N-(4-chlorobenzyl)-N-(3-cyanophenyl)-2-(dimethylamino)acetamide	 (13j)	 yield	 96	 %	 1H	 NMR	
(CDCl3)	δ	7.64	(d,	J	=	7.5	Hz,	1H,	ArH),	7.48	(t,	J	=	8	Hz,	1H,	ArH),	7.40	(s,	1H,	ArH),	7.28	(d,	J	=	8	Hz,	
2H,	ArH),	7.14	(d,	J	=	8.5	Hz,	2H,	ArH),	4.88	(s,	2H,	CH2),	2.87	(s,	2H,	CH2),	2.25	(s,	6H,	2xCH3);	13C	NMR	
(CDCl3)	 δ	 169.36	 (C=O),	 142.50	 (ArC),	 135.17	 (ArC),	 133.72	 (ArC),	 133.18	 (ArCH),	 131.95	 (ArCH),	
131.73	(ArCH),	130.51	(ArCH),	130.11	(ArCH),	128.86	(ArCH),	117.61	(CN),	113.72	(ArC),	61.14	(CH2),	
52.41	(CH2),	45.44	(2xCH3).	MS	[ESI,	m/z]:	calcd	for	C18H18ClN3O	[M+H],	328.1217;	found,	328.1233.	
N-(4-chlorobenzyl)-N-(4-cyanophenyl)-2-(dimethylamino)acetamide	 (13k)	 yield	 87	 %	 1H	 NMR	
(CDCl3)	δ	7.67	(d,	J	=	8.5	Hz,	2H,	ArH),	7.26	(d,	J	=	8.5	Hz,	2H,	ArH),	7.17	(d,	J	=	8.5	Hz,	2H,	ArH),	7.13	
(d,	 J	=	8.5	Hz,	2H,	ArH),	4.90	 (s,	2H,	CH2),	2.90	 (s,	2H,	CH2),	2.23	 (s,	6H,	2xCH3);	 13C	NMR	(CDCl3)	δ	
169.28	(C=O),	145.75	(ArC),	135.23	(ArC),	133.73	(ArC),	133.45	(ArCH),	129.97	(ArCH),	129.18	(ArCH),	
128.86	 (ArCH),	 117.91	 (CN),	 111.93	 (ArC),	 61.31	 (CH2),	 52.35	 (CH2),	 45.45	 (2xCH3).	MS	 [ESI,	 m/z]:	
328.12	 [M+H],	 350.10	 [M+Na],	 anal.	 calcd	 for	 C18H18ClN3O:	 C,	 65.95;	 H,	 5.53;	 N,	 12.81.	 Found:	 C,	
65.85;	H,	5.60;	N,	12.72.	
N-(3-cyanophenyl)-2-(dimethylamino)-N-(4-fluorobenzyl)acetamide	 (13l)	 yield	 65	 %.	 1H	 NMR	
(CDCl3)	δ	7.63	(d,	J=7.5	Hz,	1H,	ArH),	7.48	(t,	J=7.5	Hz,	1H,	ArH),	7.37	(s,	1H,	ArH),	7.24	(d,	J=7	Hz,	1H,	
ArH),	7.16	(dd,	J=	9,	5.5	Hz,	2H,	ArH),	6.99	(t,	J=8.5	Hz,	2H,	ArH),	4.88	(s,	2H,	CH2),	2.84	(s,	2H,	CH2),	
2.24	 (s,	 6H,	 2xCH3).	 13C	NMR	 (CDCl3)	δ	 165.56	 (C=O),	 162.36	 (d,	 1JC-F	 =	 245	Hz,	 ArC),	 142.54	 (ArC),	
133.21	 (ArCH),	 132.49	 (ArC),	 132.07	 (ArCH),	 131.67	 (ArCH),	 130.63	 (ArCH),	 130.45	 (ArCH),	 117.62	
(CN),	115.60	(d,	2JC-F	=	21.5	Hz,	ArCH),	113.70	(ArC),	61.20	(CH2),	52.35	(CH2),	45.47	(2xCH3).	MS	[ESI,	
m/z]:	calcd	for	C18H18FN3O	[M+H],	312.1507;	found,	312.1506.	
5-(N-(4-chlorobenzyl)-2-(dimethylamino)acetamido)-2-hydroxybenzoic	 acid	 (13m)	 yield	97	%.	The	
mixture	of	(13c;	1.5	mmol)	in	MeOH	and	aq.	1M	NaOH	(0.7	mL)	solution	was	stirred	at	60°	for	24h.	
The	mixture	was	cooled	and	1M	HCl	was	added	 for	neutralization.	The	white	product	precipitated	
and	recrystalised	from	MeOH.	1H	NMR	(MeOH-d4)	δ	7.55	(d,	J=	3	Hz,	1H,	ArH),	7.31	(d,	J=	8.5	Hz,	2H,	
ArH),	7.23	(d,	J=	8.5	Hz,	2H,	ArH),	7.00	(dd,	J=	8.5,	3	Hz,	1H,	ArH),	6.83	(d,	J=	8.5	Hz,	1H,	ArH),	4.90	(s,	
2H,	 CH2),	 3.87	 (s,	 2H,	 CH2),	 2.88	 (s,	 6H,	 2xCH3).	 13C	 NMR	 (MeOH-d4)	 173.11	 (C=O),	 164.58	 (C=O),	
162.03	(ArC),	135.16	(ArC),	133.31	(ArC),	132.03	(ArCH),	130.26	(ArCH),	130.08	(ArCH),	128.47	(ArC),	
128.30	 (ArCH),	119.97	 (ArC),	117.58	 (ArCH),	58.01	 (CH2),	52.27	 (CH2),	43.08	 (2xCH3).	MS	 [ESI,	m/z]:	
calcd	for	C18H19ClN2O4	[M+H],	363.1112;	found,	363.1127.	
Methyl	5-(bis(4-chlorobenzyl)amino)-2-methoxybenzoate	(14)	yield	93	%	1H	NMR	(CDCl3)	δ	7.31	(d,	
J=8.5	Hz,	4H,	ArH),	7.26	(d,	 J=2.5	Hz,	1H,	ArH),	7.18	(d,	J=9	Hz,	4H,	ArH),	6.85	(d,	 J=9	Hz,	1H,	ArH),	
6.82	(dd,	J=9,	3	Hz,	1H,	ArH),	4.50	(s,	4H,	2xCH2),	3.87	(s,	3H,	CH3),	3.84	(s,	3H,	CH3);	13C	NMR	(CDCl3)	
δ	167.02	(C=O),	151.79	(ArC),	142.68	(ArC),	136.67	(ArC),	132.84	(ArC),	128.80	(ArCH),	128.50	(ArCH),	
120.81	(ArC),	119.27	(ArCH),	117.07	(ArCH),	114.05	(ArCH),	56.76	(CH3),	54.60	(CH2),	52.12	(CH3).	MS	
[ESI,	m/z]:	430.12	[M+H].	calcd	for	C23H21Cl2NO3	[M+H],	430.0971;	found,	430.0972.	
5-(Bis(4-chlorobenzyl)amino)-2-methoxybenzoic	acid	(15)	yield	75	%.	1H	NMR	(CDCl3)	δ	9.57	(bs,	1H,	
COOH),	7.61	(d,	J=3	Hz,	4H,	ArH),	7.28	(d,	J=8.5	Hz,	1H,	ArH),	7.16	(d,	J=8.5	Hz,	4H,	ArH),	6.91	(d,	J=9	
Hz,	1H,	ArH),	6.88	(dd,	J=9,	3	Hz,	1H,	ArH),	4.55	(s,	4H,	2xCH2),	3.96	(s,	3H,	CH3);	13C	NMR	(CDCl3)	δ	
165.95	(C=O),	150.46	(ArC),	143.85	(ArC),	136.40	(ArC),	132.89	(ArC),	128.87	(ArCH),	128.38	(ArCH),	
120.04	 (ArCH),	 118.19	 (ArC),	 117.60	 (ArCH),	 113.37	 (ArCH),	 57.13	 (CH3),	 54.39	 (CH2).	 calcd	 for	
C22H19Cl2NO3	[M-H],	414.0669;	found,	414.0664.	
	
	
	Figure	4.	Mass	spectrum	of	compound	5c	
	
	
	
Figure	5.	1H	NMR	spectrum	of	compound	5c	
	
	
Figure	6.	13C	NMR	spectrum	of	compound	5c	
	
	
